Webcast ImageWebcast
BioTime, Inc. at Oppenheimer 27th Annual Healthcare Conference  (Replay)
03/21/17 at 3:55 p.m. ET
BioTime, Inc. at Oppenheimer 27th Annual Healthcare Conference
Tuesday, March 21, 2017 3:55 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
December 31, 2015BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common Stock
Regular Way Trading of OncoCyte common stock on NYSE MKT to begin January 4, 2016 ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 31, 2015-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, has completed its previously announced distribution of approximately 4.75 million shares of common stock of its subsidiary OncoCyte Corporation (“OncoCyte”) to BioTime shareholders. Regul... 
Printer Friendly Version
December 30, 2015BioTime Announces “When-Issued” Trading of Subsidiary OncoCyte Corporation in Connection With Planned Distribution
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 30, 2015-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the common stock of its subsidiary OncoCyte Corporation (“OncoCyte”) will begin trading today on a “when-issued” basis on the NYSE MKT under the symbol OCX WI. “Regular-way” trading of OncoCyte common stock on the NYSE MKT is expected to begin on January 4, 2... 
Printer Friendly Version
December 11, 2015BioTime Co-Chief Executive Officer Michael D. West, PhD to Deliver Keynote Speech at the 2015 World Stem Cell Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 11, 2015-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its co-Chief Executive Officer Michael D. West, PhD will deliver a keynote presentation at the 2015 World Stem Cell Summit in Atlanta, Georgia on Saturday, December 12, 2015 from 11:30am to 12:30pm EST. Dr. West’s lecture is titled, “Emerging Trends in ... 
Printer Friendly Version
December 11, 2015BioTime, Inc. Announces Record Date, Distribution Ratio, and Distribution Date for Distribution of Shares of Subsidiary OncoCyte Corporation
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 11, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its Board of Directors has set the record date, the distribution ratio, and expected distribution date for the distribution of a portion of the shares of common stock of BioTime’s subsidiary OncoCyte Corporation (“OncoCyte”) to BioTime shareholders. ... 
Printer Friendly Version
December 04, 2015BioTime, Inc. to Present at Oppenheimer Annual Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 4, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty, Co-Chief Executive Officer, is scheduled to present at the Oppenheimer 26th Annual Healthcare Conference in New York City to be held on December 8-9, 2015. Mr. Mohanty will provide an overview of the Company and an update on product devel... 
Printer Friendly Version
November 18, 2015BioTime, Inc. Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 18, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Company’s Board of Directors has appointed Russell Skibsted to the position of Chief Financial Officer, succeeding Robert Peabody. Mr. Russell Skibsted brings over 25 years of financial management and life sciences business experie... 
Printer Friendly Version
November 09, 2015BioTime, Inc. Reports Third Quarter 2015 Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 9, 2015-- BioTime, Inc. (NYSE MKT and TASE:BTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its recent accomplishments. “During the third quarter, BioTime and its family of companies achieved significant progress on multiple fronts,” said Adi Mohanty, BioTime’s co-Chief Executive Officer. “We are delivering on our commitment to reduce the c... 
Printer Friendly Version
November 06, 2015BioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to Address the In Vitro Cell Biology Market
Combination of BioTime’s ESI BIO Division and Hepregen to Focus on Next-Generation Metabolism and Safety Screening of New Drugs and Chemicals Provides Access to Hepregen’s Current Customer Base of Major Pharmaceutical and Chemical Companies BioTime Retains Cell Therapy Opportunities While Gaining Entry to Drug Screening Industry ALAMEDA, Calif. & MEDFORD, Mass.--(BUSINESS WIRE)--Nov. 6, 2... 
Printer Friendly Version
October 19, 2015Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime, Inc.
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 19, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, reported today that its Board of Directors has appointed Adi Mohanty to serve with Michael D. West, PhD, as co-Chief Executive Officer. Mr. Mohanty has served as BioTime’s Chief Operating Officer since December 2014. Dr. West will lead BioTime’s science, technology devel... 
Printer Friendly Version
October 07, 2015BioTime’s Subsidiary OncoCyte Corporation Files Form 10 Registration Statement for Planned Distribution
BioTime Plans Distribution of Shares of Subsidiary OncoCyte Corporation to BioTime Shareholders Planned Distribution to Allow OncoCyte Greater Access to Capital Markets as a Publicly Traded Company ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 7, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, and its subsidiary OncoCyte Corpo... 
Printer Friendly Version
October 02, 2015BioTime, Inc. Agrees to Sell $5.1 Million of Equity
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 2, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it has agreed to sell 1,600,000 of its common shares, no par value, at an offering price of $3.19 per share to its largest shareholder, Broadwood Partners, L.P. (“Broadwood”). Neal Bradsher, a BioTime director, is the President of the investment manag... 
Printer Friendly Version
October 01, 2015BioTime Announces the Closing of a $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered
- Offering Priced at $3.13 Per Share - Inclusion in Six Major Indexes of the Tel Aviv Stock Exchange ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 1, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that BioTime completed a registered direct offering of 6,530,612 shares to a select group of TASE Indexes and mutual funds. The total p... 
Printer Friendly Version
September 28, 2015BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Sep. 28, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for OpRegen®, a cell-based therapeutic product consisting of retinal pigment epithelial (RPE) cells designed to block the progression of the severe dry-form of age-related macular degenerat... 
Printer Friendly Version
September 25, 2015BioTime, Inc. Agrees to Sell Up to $20.7 Million of Common Shares
Shares to be sold to TASE Index Funds in Israel ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 25, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell up to $20.7 million of its common shares in a registered direct offering to select investment funds in Israel that hold shares of companies that are included within certain stock indexes of the Tel Aviv Stock Exchange (the “TASE”). The price per share will be determined wit... 
Printer Friendly Version
September 14, 2015BioTime, Inc. Agrees to Sell $8.58 Million of Common Shares
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 14, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell 2,607,401 of its common shares, no par value, at an offering price of $3.29 per share, for a gross purchase price of approximately $8.58 million, to selected investors, including a major shareholder, Broadwood Partners, L.P. (“Broadwood”), in a registered direct offering. The price per share was the closing price of BioTime ... 
Printer Friendly Version
September 04, 2015BioTime Announces Dual Listing on the Tel Aviv Stock Exchange
- Common shares are currently listed on NYSE MKT and will also be listed on the Tel Aviv Stock Exchange (TASE) beginning September 8, 2015 under ticker symbol BTX - Anticipated inclusion in the TASE: TA-75, TA-100, TA-BlueTech, TA-Tech-Elite and TA-Biomed Indexes ALAMEDA, Calif. & TEL AVIV, Israel--(BUSINESS WIRE)--Sep. 4, 2015-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company focused on the development and commercialization... 
Printer Friendly Version
September 02, 2015ESI BIO - A Division of BioTime, Inc. Launches New Research Technology Platform, VascuNet™ Pericyte Co-Culture Assay
Provides Researchers with In Vitro Assays with Greater Physiological Relevance and Accuracy ALAMEDA, Calif., September 2, 2015 – ESI BIO (esibio.com), the stem cell products division of BioTime, Inc., announced today the release of its most recent technology platform designed to give researchers new standardized in vitro assays with greater physiological relevance and accuracy. The VascuNet™ Pericyte Co-Culture Assay provides a stable, clinically relevant angiogenesis model not c... 
Printer Friendly Version
September 01, 2015BioTime Chief Executive Officer Dr. Michael D. West to be Keynote Speaker at Stem Cells & Regenerative Medicine Congress 2015
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 1, 2015-- BioTime, Inc. (NYSE MKT:BTX) announced today that its Chief Executive Officer Michael D. West, Ph.D. will deliver a keynote presentation at the Stem Cells & Regenerative Medicine Congress in Washington, D.C. from 9:30 to 10:00 a.m. EDT on Wednesday, September 2, 2015. Dr. West’s lecture is titled, “The Replicative Immortality of the Germ-Line: Implications for the Application of Regenerative Medicine i... 
Printer Friendly Version
August 28, 2015BioTime Management to Present at Rodman & Renshaw 17th Annual Global Investment Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 28, 2015-- BioTime, Inc. (NYSE MKT:BTX) announced today that BioTime management will present at the Rodman & Renshaw 17th Annual Investment Conference in New York City from 3:00 to 3:25 p.m. EDT on Thursday, September 10, 2015. Investors will receive an update on BioTime and its subsidiaries. The investor presentation will also be available for a live webcast by clicking on the following link: http://www... 
Printer Friendly Version
August 10, 2015BioTime, Inc. Reports Second Quarter 2015 Results and Recent Developments
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 10, 2015-- BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the second quarter ended June 30, 2015 and provided a corporate update. “BioTime’s management team has sharpened its focus on our high priority programs,” said Dr. Michael D. West, BioTime’s Chief Executive Officer. “Our strategy for achieving the leadership role in regenerative medicine includes: continuing to advance the ongoing c... 
Printer Friendly Version
August 10, 2015BioTime Announces the Issuance of 27 New Patents Protecting Stem Cell-Based Product Development
New patents add to existing portfolio of over 700 issued and pending patents and patent applications world wide owned or licensed to BioTime or its subsidiaries ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 10, 2015-- BioTime, Inc. (NYSE MKT:BTX) today announced that 27 new patents have issued during the first half of 2015 that are owned or licensed to BioTime or its subsidiaries. These new patents add to the portfolio of over 700 issued ... 
Printer Friendly Version
May 20, 2015BioTime to Present at the Jefferies 2015 Global Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--May 20, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced that Chief Executive Officer Michael D. West, PhD will present at the Jefferies 2015 Global Healthcare Conference to be held in New York on June 1-4, 2015. Dr. West will provide an overview of the company and an update on product development in his presentation at 3:00 PM EDT on Wednesday, June 3, 2015. Attendance at the conference is by invitati... 
Printer Friendly Version
May 13, 2015BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s Office of the Chief Scientist
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--May 13, 2015-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2015 of 6.24 million shekels (approximately $1.61 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product that consists of animal product-free retinal pigm... 
Printer Friendly Version
May 11, 2015BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--May 11, 2015-- BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the first quarter ended March 31, 2015 and provided a corporate update. “BioTime continues to advance its strategic product development programs. We are currently enrolling patients in a pivotal trial of Renevia™ for the treatment of HIV-associated lipoatrophy,” said Dr. Michael D. West, BioTime’s Chief Executive Officer. “At this ye... 
Printer Friendly Version
May 04, 2015Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision
Data to be Presented at Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--May 4, 2015-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that preclinical data demonstrating that Cell Cure’s product candidate, OpRegen®, preserved vision and retinal structure when transplanted into the leading animal model of r... 
Printer Friendly Version
April 27, 2015BioTime’s Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington’s Disease
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 27, 2015-- BioTime, Inc. (NYSE MKT:BTX) today announced that the clinical-grade human Embryonic Stem (hES) cell lines from BioTime’s wholly-owned subsidiary ES Cell International Pte Ltd (ESI, Singapore) will be used by UC Irvine scientist Dr. Leslie Thompson to continue her promising research in the use of stem cells to treat Huntington’s disease under a $5 million grant from the California Institute for Regenerati... 
Printer Friendly Version
April 22, 2015BioTime Licenses Beckman Research Institute of City of Hope to Manufacture Clinical Grade Stem Cells
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 22, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced a nonexclusive License Agreement between BioTime’s subsidiary ES Cell International Pte Ltd (ESI) and Beckman Research Institute of the City of Hope (BRICOH, Duarte, CA) through which ESI’s clinical-grade human embryonic stem (hES) cells will be manufactured and provided to BRICOH’s clinical collaborators, including medical research organizations intent on usi... 
Printer Friendly Version
April 20, 2015Positive Clinical Results of OncoCyte’s PanC-Dx™ Diagnostic Test Demonstrate High Level of Sensitivity and Specificity in Non-Invasive Detection of Bladder Cancer
Data Presented at American Association for Cancer Research 2015 Annual Meeting ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 20, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced positive clinical results of PanC-Dx™, OncoCyte’s class of proprietary, non-invasive cancer diagnostic tests, in detecting the most common type of bladder cancer, urothelial carcinoma (UC). Karen B. Chapman, PhD, Vice President of Re... 
Printer Friendly Version
March 11, 2015BioTime, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 11, 2015-- BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the quarter and year ended December 31, 2014, and highlighted its fourth quarter and recent corporate accomplishments. “In 2014, BioTime and its subsidiaries built strong momentum in advancing the development of therapeutic and diagnostic products that address unmet medical needs with large market potential,” said Dr. Michae... 
Printer Friendly Version
February 24, 2015BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia™ for HIV-Associated Lipoatrophy
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 24, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced that the first patient was successfully treated in the Company’s pivotal clinical trial in Europe assessing the efficacy of Renevia™ for the treatment of HIV-associated lipoatrophy. HIV-associated lipoatrophy is a disorder characterized by abnormal loss of body fat from under the skin that occurs in almost half of the approximately three million people on ... 
Printer Friendly Version
February 23, 2015ESI BIO – A Division of BioTime, Inc., Announces Alliance Agreement with Pivotal Scientific Ltd for Distribution of Stem Cell Products
ALAMEDA, Calif., February 23, 2015 – ESI BIO, the stem cell products division of BioTime, Inc., providing stem cells and stem cell research reagents world-wide, and Pivotal Scientific Ltd, a company specializing in developing the international growth of biotech enterprises, announced an alliance agreement to develop business opportunities and manage ESI BIO’s growing network of new international distributors. ESI BIO’s (esibio.com) research products are used by stem cell resear... 
Printer Friendly Version
February 17, 2015Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 17, 2015-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today provided an update on Cell Cure’s product development and partnering activities. On February 16, 2015, Cell Cure opened the clinical trial of OpRegen® titled “Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells ... 
Printer Friendly Version
January 27, 2015ESI BIO - A Division of BioTime, Inc. Announces New UK Distribution Agreement with 2BScientific
ALAMEDA, Calif., January 27, 2015 – ESI BIO, the stem cell products division of BioTime, Inc., announces that its cGMP and research grade stem cell lines, reagents and cell matrix products are now available in the UK and Ireland through 2BScientific Ltd. ESI BIO’s (esibio.com) research products are used by stem cell researchers around the world and include clinical and research grade human embryonic stem cells from ES Cell International (ESI) and HyStem® hyaluronan-based hydrogel ex... 
Printer Friendly Version
January 26, 2015BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 26, 2015-- BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc. (NYSE MKT: AST), OrthoCyte Corporation, ES Cell International Pte Ltd, OncoCyte Corporation, and ReCyte Therapeutics, Inc. The new patents issued over Q3 and Q4 of 2014 add to the BioTime family of companies’ paten... 
Printer Friendly Version